A research team identified Ru5 as a potent antitumor agent by screening a panel of ruthenium(II) polypyridine complexes containing β-carboline derivatives as ligands. By employing a photoaffinity tag and utilizing the photoaffinity-based protein profiling technology, the researchers successfully elucidated mitochondrial ATPase as the primary molecular target of Ru5.
Ru5 identified as potent antitumor agent targeting mitochondrial ATPase
